Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: To investigate the effects of pattern scanning laser (Pascal; OptiMedica, Santa Clara, California) multispot panretinal photocoagulation given in a single-session (SS-PRP) vs single-spot multiple-session PRP (MS-PRP) on proliferative diabetic retinopathy (PDR).
Methods: Single-center, randomized clinical trial of 40 eyes. Proliferative diabetic retinopathy was treated with a 400-mum spot size in 1500 burns given either as Pascal in 20-millisecond SS-PRP or in 3 sessions (100-millisecond MS-PRP) during a 4-week period. Visual acuity, central subfield retinal thickness (CRT), and 24-2 Swedish interactive thresholding algorithm visual fields were recorded at baseline and 4 and 12 weeks.
Main Outcome Measures: Central subfield retinal thickness, mean deviation, and PDR grade at 12 weeks.
Results: There was a significant increase in mean CRT with MS-PRP (22 mum at 4 weeks, 95% CI, -32.25 to -10.75; 20 mum at 12 weeks, 95% CI, -28.75 to -10.82; P < .001) and no significant increase in the SS-PRP group. The mean deviation increased significantly in the SS-PRP group after 4 weeks (0.73 dB, P = .048), with no significant changes in either group at other points. A positive effect on PDR was observed in 74% of eyes in the SS-PRP group vs 53% in the MS-PRP group (P = .31). Mean treatment time for SS-PRP was 5.04 minutes (SD, 1.5 minutes) compared with 59.3 (SD, 12.7 minutes) in the MS-PRP group (P < .001).
Conclusions: There were no adverse outcomes (CRT, visual acuity, or visual field) from using multispot SS-PRP vs single-spot MS-PRP at 12 weeks postlaser, and treatment times were significantly shorter for multispot SS-PRP. Pascal SS-PRP was as effective as MS-PRP in the treatment of PDR.
Application To Clinical Practice: Twenty-millisecond Pascal SS-PRP may be safely and rapidly performed in 1500 burns with a similar efficacy to conventional MS-PRP. TRIAL IDENTIFIER: Research and Development Office PIN R00037, Central Manchester University Hospitals Foundation Trust.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archophthalmol.2010.60 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Expanded field OCTA Biomarkers Associated with the Development of Tractional Retinal Detachment in Proliferative Diabetic Retinopathy.
Retina
September 2025
Harvard Retinal Imaging Lab, Massachusetts Eye and Ear, Boston, MA, USA.
Purpose: To investigate associations among expanded field swept-source optical coherence tomography angiography (SS-OCTA) biomarkers and the development of tractional retinal detachment (TRD) in patients with proliferative diabetic retinopathy (PDR).
Methods: Patients with PDR without TRD at baseline were imaged with SS-OCTA. Quantitative and qualitative OCTA metrics were independently evaluated by two trained graders.
Iris cerclage with goniosynechialysis and canalicular stent for neovascular angle closure glaucoma.
Am J Ophthalmol Case Rep
September 2025
Columbia University Medical Center, Norwalk, Connecticut, USA.
Purpose: To report a surgical treatment for neovascular angle closure glaucoma.
Observations: A 69 year-old man with proliferative diabetic retinopathy developed neovascular angle closure with intraocular pressure (IOP) 60 mm Hg. Surgical goniosynechialysis and placement of a Hydrus canalicular stent were combined with pupilloplasty using an iris cerclage suture to maintain tension on the peripheral iris to limit reformation of goniosynechiae.
Assessing the Diagnostic Capabilities of ChatGPT-4 Omni in Grading Diabetic Retinopathy Fundoscopy Using Color Fundus Photographs.
Clin Ophthalmol
August 2025
University of Virginia School of Medicine, Charlottesville, VA, USA.
Purpose: Diabetic retinopathy (DR) is a leading cause of vision loss in working-age adults. Despite the importance of early DR detection, only 60% of patients with diabetes receive recommended annual screenings due to limited eye care provider capacity. FDA-approved AI systems were developed to meet the growing demand for DR screening; however, high costs and specialized equipment limit accessibility.
View Article and Find Full Text PDFIntravitreal anti-VEGF therapy and risk of limb complications in individuals with diabetic eye disease.
Diabetes Res Clin Pract
September 2025
Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Aims: To evaluate the association between intravitreal anti-VEGF therapy and lower extremity complications in diabetic eye disease (DED), and compare risks among ranibizumab, aflibercept, and bevacizumab.
Methods: This retrospective cohort study used a U.S.
Association between haemoglobin levels and the risk of diabetic retinopathy in adults with type 2 diabetes: a retrospective cohort study using the TriNetX network.
Eye (Lond)
September 2025
Department of Anesthesiology, Chi Mei Medical Center, Liouying, Tainan city, Taiwan.
Background: Diabetic retinopathy (DR) is the leading cause of preventable blindness. Although hyperglycaemia is the primary driver, other modifiable risk factors may contribute to DR development. This study investigated the association between haemoglobin levels and DR risk in adults with type 2 diabetes.
View Article and Find Full Text PDF